PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Por Serra, V, Scaltriti, M, Prudkin, L, Eichhorn, P J A, Ibrahim, Y H, Chandarlapaty, S, Markman, B, Rodriguez, O, Guzman, M, Rodriguez, S, Gili, M, Russillo, M, Parra, J L, Singh, S, Arribas, J, Rosen, N, Baselga, J
Publicado em 2011

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

Por Cruz, C, Castroviejo-Bermejo, M, Gutiérrez-Enríquez, S, Llop-Guevara, A, Ibrahim, Y H, Gris-Oliver, A, Bonache, S, Morancho, B, Bruna, A, Rueda, O M, Lai, Z, Polanska, U M, Jones, G N, Kristel, P, de Bustos, L, Guzman, M, Rodríguez, O, Grueso, J, Montalban, G, Caratú, G, Mancuso, F, Fasani, R, Jiménez, J, Howat, W J, Dougherty, B, Vivancos, A, Nuciforo, P, Serres-Créixams, X, Rubio, I T, Oaknin, A, Cadogan, E, Barrett, J C, Caldas, C, Baselga, J, Saura, C, Cortés, J, Arribas, J, Jonkers, J, Díez, O, O’Connor, M J, Balmaña, J, Serra, V
Publicado no Ann Oncol (2018)